Wave Life Sciences’ stock soars 51% after biotech posts positive data from Duchenne muscular-dystrophy trial

[ad_1]

Biotech reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder Duchenne muscular dystrophy.

[ad_2]

Source link